GRANJET 60

Granjet-60 Injection – Artesunate 60 mg

When severe malaria requires rapid parenteral antimalarial treatment in a clinical setting, Granjet-60 Injection by Grantham Lifesciences provides an injectable artesunate formulation for use under professional medical supervision. Each vial contains Artesunate IP 60 mg. The product is labeled for I.M./I.V. use only. Artesunate injection is recommended for the treatment of severe malaria and is generally followed by an appropriate oral antimalarial regimen once the patient can tolerate oral therapy.

Why Granjet-60 Injection stands out:

• Contains Artesunate IP 60 mg, an artemisinin-based antimalarial.

• Intended for parenteral treatment of severe malaria when injectable artesunate is indicated. Supplied as a powder for injection, requiring preparation before administration.

• The pack shown includes the artesunate vial along with accompanying reconstitution/dilution components.

• Labeled for I.M./I.V. use only.

• Convenient 60 mg/vial presentation.

• Manufactured by Grantham Lifesciences. The manufacturer’s product list identifies Granjet 60 as Artesunate 60 mg injection and categorizes it as an antimalarial.

Uses & Indications

Granjet-60 Injection may be prescribed for the treatment of severe malaria caused by susceptible Plasmodium species. WHO recommends intravenous or intramuscular artesunate for adults and children with severe malaria, followed by completion of antimalarial treatment with an appropriate oral regimen once oral therapy can be tolerated. WWorld Health Organization+1

Artesunate is particularly important when rapid parenteral antimalarial therapy is required or when oral medication cannot initially be taken reliably.

Key Benefits

• Provides artesunate 60 mg in an injectable formulation.

• Designed for rapid parenteral antimalarial therapy in appropriate clinical situations.

• Can be administered by the I.V. or I.M. route, according to the product labeling and medical instructions.

• Useful when oral antimalarial administration is not initially appropriate.

• Supplied as a powder that is prepared before administration.

Dosage & Administration

Granjet-60 should be prepared and administered only by a qualified healthcare professional.

The appropriate dose is determined according to the patient’s body weight, age, clinical condition, severity of malaria, and treatment protocol. WHO guidance uses weight-based dosing for parenteral artesunate; the exact regimen should be determined by the treating clinician. WWorld Health Organization+1

The injection should be reconstituted using the supplied components according to the manufacturer’s instructions. Do not self-administer or prepare the injection without professional training.

Possible Side Effects

Artesunate injection is generally well tolerated, but adverse effects may occur. Possible effects include:

• Nausea or vomiting

• Headache

• Dizziness

• Fever or chills

• Injection-site reactions

• Changes in blood counts

• Delayed hemolytic anemia after treatment in some patients

Delayed hemolysis has been reported following injectable artesunate, and appropriate clinical monitoring may be required after treatment.

Any severe, unusual, or persistent symptoms should be reported promptly to a healthcare professional.

Precautions & Interactions

Inform the treating doctor about all existing medical conditions and medicines being used before receiving Granjet-60.

Special medical attention may be required in patients with:

• Previous allergy to artesunate or other artemisinin medicines

• Significant anemia or blood disorders

• Pregnancy or breastfeeding

• Other serious medical conditions

Because severe malaria itself can be life-threatening, treatment should be provided in an appropriate healthcare setting with monitoring and supportive care.

Storage Instructions

The exact storage conditions should be followed according to the current product label/package insert.

For injectable artesunate products, WHO-prequalified presentations are generally stored protected from light and should not be frozen; storage requirements can vary by manufacturer and formulation.

• Keep out of reach of children.

• Protect the product from inappropriate heat, light, and moisture.

• Do not use beyond the expiry date.

• Prepared solution should be handled according to the manufacturer’s instructions.

Packaging & Product Information

Product Name: Granjet-60 Injection
Manufacturer: Grantham Lifesciences
Dosage Form: Injection
Strength: 60 mg/Vial
Composition: Artesunate IP 60 mg
Category: Antimalarial
Form: Powder for injection
Route: I.M./I.V. use only
Pack: 60 mg
MRP: ₹206/-
GST: 5%
Website: Grantham Lifesciences

Note: The MRP and GST above are transcribed from the product image you provided. The manufacturer’s older product lists show different commercial pricing/tax information, so the current printed pack should be treated as authoritative for the specific batch. 

Frequently Asked Questions (FAQs)

Q1. What is Granjet-60 Injection?
A. Granjet-60 is an injectable antimalarial containing Artesunate IP 60 mg. It is labeled for I.M./I.V. use and is intended for administration by a healthcare professional.

Q2. What is Granjet-60 Injection used for?
A. It is used for the treatment of severe malaria when parenteral artesunate therapy is indicated.

Q3. How is Granjet-60 administered?
A. The product is labeled for intravenous or intramuscular administration. It must first be properly prepared and should be administered by a qualified healthcare professional.

Q4. Can Granjet-60 be self-administered?
A. No. It is a prescription injectable medicine and should only be prepared and administered under appropriate medical supervision.

Q5. What does each vial contain?
A. Each vial contains Artesunate IP 60 mg. The pack shown also contains accompanying components used for preparation of the injection.

Q6. What are the possible side effects?
A. Possible adverse effects include nausea, vomiting, headache, dizziness, injection-site reactions, blood-count abnormalities, and delayed hemolysis. W

Q7. Is Granjet-60 used for ordinary fever?
A. No. Artesunate injection is an antimalarial medicine and should not be used for an undiagnosed fever or other conditions without medical assessment.

Q8. Is Granjet-60 a prescription medicine?
A. Yes. It is an injectable antimalarial intended for use under the direction of a qualified healthcare professional.

Medical Disclaimer

Granjet-60 Injection is a prescription antimalarial medicine. The information above is intended for product-information purposes and does not replace malaria diagnosis, prescribing, dose selection, preparation, or administration by a qualified healthcare professional. Severe malaria can progress rapidly and requires urgent medical care.